Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Mol Cancer Ther. 2014 Feb 21;13(5):1044–1053. doi: 10.1158/1535-7163.MCT-13-0550

Figure 5. AEB071/BYL719 combination inhibits in vivo tumor growth in a GNAQ mutant xenograft model.

Figure 5

A, AEB071/BYL719 inhibited tumor growth in a xenograft model with the GNAQ mutant 92.1 cell line. 6-8 week nu/nu SCID female mice were subcutaneously injected with 92.1 cells. Drug treatments began after tumors reached 100 mm3. Mice with tumors were treated three times daily with AEB071 (80mg/kg/d) or once daily with BYL719 (50 mg/kg/d) or in combination for 5 days each week for a total of 2 weeks. Tumors were measured with calipers every 2 to 3 days. Tumor volume was compared between groups of mice at various time points. P-value when compared to either AEB071 or BYL719 alone p = 0.049 vs. BYL719 and p= 0.022 vs. AEB071 at day 26. Toxicity was measured by weight loss (right panel). B, Two animals from each cohort were sacrificed and tumors were collected on Day 26. Tumors were lysed with RIPA buffer and Western blots were performed for pAKT, pERK, pS6, pMARCKS and αtubulin.